Commentary
Giovenzio Genestreti, Monic
Abstract
Small cell lung cancer (SCLC) has typically high sensitivity to chemotherapy and radiotherapy, although greater part of patients with limited disease (LD) and all patients with extended disease (ED) will develop disease relapse or progression, with an overall survival of 2-4 months in case of only best supportive care